LSI Her-2/neu (Orange)

« back

Probe location


Probe description

The Her-2/neu FISH kit is intended for the determination of Her-2/neu gene amplification in human tissues using fluorescence in situ hybridization (FISH).
The Her-2/neu FISH kit contains a directly labeled fluorescent DNA probe in hybridization buffer. The fluorochrome Orange labeled Her-2/neu probe covers the chromosome 17q11-12 region. The Her-2/neu (Human Epidermal Growth Factor Receptor 2 also known as Neu) gene codes for a 185 kDa transmembrane receptor with tyrosine kinase activity and belongs to the EGF (epidermal growth factor) receptor family. Her-2/neu gene is amplified in 15-30% of breast cancer, and less frequently in other cancers, e. g. lung, pancreatic, ovarian, or stomach cancesr. The Her-2/neu gene amplification is strongly associated with increased disease recurrence and worse prognosis. Breast cancer patients with Her-2/neu gene amplification are treated with monoclonal antibody p185Her-2 trastuzumab (Herceptin) and/or tyrosin kinase inhibitors (lapatinib, Tyverb).

FISH results

Normal cell (Fig.1a) shows 2 orange signals (Her-2/neu). An abnormal cell (Fig.1b) shows higher copy number of Her-2/neu gene.

A normal cell in FFPE tissue hybridized with LSI Her-2/neu (Orange) shows 2 orange signals of Her-2/neu gene. An abnormal cell in FFPE tissue hybridized with LSI Her-2/neu (Orange) shows a higher copy number of Her-2/neu gene.
1a 1b
Figure. 1. Assessment of the copy number of Her-2/neu  gene in FFPE tissue (breast cancer patient tissue).
1a) 2 copies of Her-2/neu gene in cell.
1b) Higher copy number of Her-2/neu gene in cell (amplification).



Catalogue number

Packing size


Instruction for use

LSI Her-2/neu (Orange)



upon request




  • Slamon DJ, Clark GM, Wong SG: Human breast cancer: Correrlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 1987; 235: 177-182. [fulltext]
  • Perez EA: Her2 as a prognostic, predictive, and therapeutic target in breast cancer, JMCC 1999; 6: 233-240. [fulltext]
  • Shak S: Overview of trastuzumab (Herceptin) anti-Her2 monoclonal antibody clinical program in Her2- overexpressing metastatic breast cancer. Semin Oncol 1999; 26: 71-7. [fulltext]
  • Ross JS, Fletcher JA: The  Her-2/neu oncogene : prognostic factor , predictive factor and target for the therapy. Semin Cancer Biol 1999; 9: 125-138. [fulltext]
  • Lebeau A, Deimling D, Kaltz Ch., Sendelhofert, Iff A, Luthardt B, Untch M, Löhrs U: Her-2/neu analysis in archival tissue samples of human breast cancer: comparsion of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001;19: 354-63. [fulltext]